| 翻訳と辞書 |
NGD-4715
NGD-4715 is a drug developed by Neurogen, which acts as a selective, non-peptide antagonist at the melanin concentrating hormone receptor MCH1. In animal studies it has anxiolytic, antidepressant and anorectic effects,〔Chaki S, Kanuma K. Neuropeptide receptors: Novel therapeutic targets for depression and anxiety disorders. ''Drugs of the Future''. 2007;32(9):809.〕 and it has successfully passed Phase I clinical trials in humans.〔(Neurogen Announces Results of First-in-Human Trial for New Approach to Treating Obesity. Business Wire. May 2 2007 )〕
Neurogen was acquired by Ligand Pharmaceuticals in August, 2009, and NGD-4715 was not listed among the key assets in the Business Wire article.〔(Neurogen acquired by Ligand Pharmaceuticals. Business Wire. August 24, 2009 ).〕 All four laboratories were closed and sold, and no employees were retained.〔(Neurogen to sell Real Estate for $3.5m. Chicago Tribune. Nov 10, 2009 )〕 (Neurogen's domain name ) is delisted. No reference to NGD-4715, nor MCH Antagonists exists on (ligand.com ) as of 2011-09-04. Internet searches as of 2011-09-04 for Phase-II come up negative.
An email to Ligand Investor Relation received this response on 2011-09-07:
"NGD-4715, a MCH-1 antagonist, was under development at Neurogen for obesity. Neurogen terminated the program prior to Ligand’s acquisition. Ligand owns the rights and currently has no plans for further development on the compound."
==References==
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「NGD-4715」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|